Loading…
Hosted by Unknown Host · 🇺🇸 US · EN · 500 episodes
Established thought leaders with verified media credentials.
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Unknown Host hosts OncLive® On Air, a health show with 500 episodes published.
Highlights from the PER® CME activity "Key Considerations for Health Equity and Patient-Centered Care in TNBC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credi
In today’s episode, we spoke with Adam M. Brufsky, MD, PhD, about the FDA approval of gedatolisib (Revtorpyk) plus fulvestrant (Faslodex), with or without palbociclib (Ibrance), for the treatment of adult patients with h
In today’s episode, we spoke with Jonathan Trent, MD, PhD, a professor in the Department of Medicine in the Division of Medical Oncology, associate director of Clinical Research, and the director of the Sarcoma Medical R
In this episode of Oncology Unplugged , host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Stephen V. Liu, MD, the division chief of Hematology Oncology at MedS
Highlights from the PER® CME activity "From Trials to the Clinic ‒ Incorporating New Advances in Metastatic TNBC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME cr
In today’s episode, we welcomed Douglas W. Sborov, MD, MS, to discuss the significance of the July 2026 FDA approval of isatuximab-irfc (Sarclisa Escena) for subcutaneous injection for multiple myeloma indications. Dr Sb
In today's episode, we spoke with Solange Peters, MD, PhD. Dr Peters is a full professor, and chair of medical oncology and the thoracic malignancies programme in the Department of Oncology at the University Hospital of
In today’s episode, we spoke with John N. Allan, MD. Dr Allan is an associate attending physician at New York-Presbyterian Hospital and an associate professor of clinical medicine at Weill Cornell Medical College in New
In today’s episode, we welcomed Everett Meyer, MD, PhD, an associate professor of medicine (blood & marrow transplantation), an associate professor of pediatrics (stem cell transplantation), and an associate professor of
In today’s episode, we spoke with Paolo Tarantino, MD, PhD. Dr Tarantino is a breast medical oncologist and advanced fellow at Dana-Farber Cancer Institute and Harvard Medical School in Boston, Massachusetts. In our excl
In today’s episode, we spoke with Sara M. Tolaney, MD, MPH, about the FDA approval of sacituzumab govitecan plus pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the first-lin
In today’s episode, we spoke with Jorge E. Cortes, MD, and Elias Jabbour, MD. Dr Cortes is the chief of Hematology in the Division of Hematology and Oncology and the associate director for Translation at the UAB O’Neal C
Highlights from the PER® CME activity "Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management" — this podcast is not certified for credit. To participate
Highlights from the PER® CME activity "Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia" — this podcast is not certified for credit. To participate in the full
Highlights from the PER® CME activity "ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions" — this podcast is not certified for credit. To participate in the full accr
Two Onc Docs , hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver
Highlights from the PER® CME activity "Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit,
In today’s episode, we spoke with Neil D. Gross, MD, FACS. Dr Gross is the medical director of Perioperative Surgical Services, section chief of Oropharynx Cancer, Surgery, and professor of head and neck surgery at The U
Highlights from the PER® CME activity "Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis" — this podcast is not certified for credit. To participate i
Highlights from the PER® CME activity "Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology" — this podcast is not certified for credit. To participate in the full acc
Jacob Sands
Dr. · Dana-Farber Cancer Institute
1 appearance on this show
Priyanka Sharma
Head of Technology Laws and Data Privacy · The University of Kansas Cancer Center
1 appearance on this show
Adam M. Brufsky
University of Pittsburgh School of Medicine
1 appearance on this show
Jonathan Trent
University of Miami Miller School of Medicine
1 appearance on this show
Stephen V. Liu
MedStar Georgetown University Hospital
1 appearance on this show
Jorge E. Cortes, MD
UAB O’Neal Cancer Center
1 appearance on this show
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center
1 appearance on this show
Sara Nunnery, MD, MSCI
Tennessee Oncology
1 appearance on this show
MinhTri Nguyen, MD
Rush MD Anderson Cancer Center
1 appearance on this show
Joshua Richter, MD
Mount Sinai
1 appearance on this show
Karine Tawagi
University of Illinois in Chicago
2 appearances on this show
Samantha A. Armstrong
Indiana University Health
2 appearances on this show
Detected from recent episode content. Sponsor presence is a real signal of listener purchasing power and show monetisation.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch OncLive® On Air, visit https://www.onclive.com/meetings/soss for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent health coverage.
OncLive® On Air is hosted by Unknown Host. The show is categorised under health (fitness) and has published 500 episodes.
OncLive® On Air has published 500 episodes.
OncLive® On Air regularly covers health, fitness, science. It sits in the health category, with a fitness focus.
OncLive® On Air is accessible for guests with genuine health expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
OncLive® On Air hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of OncLive® On Air average 19 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates OncLive® On Air's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 6 days ago.